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The circadian rhythm controls a range of important biological behaviors with a 
24-hour cycle. The mammalian biological clock is a layered network of vibrators with 
a master clock locating in the neurons of suprachiasmatic nucleus (SCN) in the 
hypothalamus and a set of core and related circadian genes. Several lines of evidence 
from previous studies suggested the relationships between tumorigenesis and 
circadian rhythm disruption. However, the effects of circadian genetic factors in 
cancer survival remains uncertain. Therefore, it is important to review and explore the 
circadian genetic factors which might be linked to cancer survival. This paper aimed 
to evaluate the potential associations between circadian genetic factors and cancer 
survival by summarizing 30 epidemiological studies and searching 2 databases. The 
circadian genetic factors identified included both gene expression and SNPs. Our 
results showed that 16 circadian genes, PER1, PER2, PER3, CRY1, CRY2, BMAL1, 
CLOCK, NPAS2, NPAS3, TIMELESS, RORA, RORC, NR1D2, CK1ε, DEC1 and 
TIPIN, were significantly related to cancer survival across several types of cancer. 
The associations between circadian genes and cancer survival differed among 
different genes and cancer types. 
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Circadian rhythm controls a wide range of important biological behaviors in a 24-
hour cycle, which responds to light and darkness, and affects many organisms, 
including animals, plants and microorganisms. In mammals, the biological clock 
controls all aspects of physiology, including sleep, metabolism and the regulation of 
the immune system. (Rijo-Ferreira, 2019) The mammalian biological clock is a 
layered network of vibrators with a master clock locating in the neurons of 
suprachiasmatic nucleus (SCN) of the anterior hypothalamus. SCN is entrained by the 
light-dark cycle and synchronizes the phases of multiple peripheral clocks in different 
peripheral tissues. (Reppert and Weaver, 2002) 
At the molecular level, circadian clocks are cellular autonomic and involve a core 
set of circadian genes, which are implicated in susceptibility and prognosis of cancers 
by involving in the regulation of DNA damage and repair, carcinogen metabolism and 
detoxification, cell proliferation, apoptosis, and cell cycle. (Zmrzljak and Rozman, 
2012) The primary circadian clock pathway genes in mammals are involved in 
transcriptional self-regulating feedback loop, including CLOCK, Brain and Muscle 
ARNT-Like 1 (BMAL1), period 1 (PER1), period 2 (PER2), cryptochrome 1 (CRY1), 
cryptochrome 2 (CRY2), REV‐ERBα (also known as NR1D1), RORA, and casein 
kinase 1-epsilon/ delta (CK1ε/δ) (Buhr et al., 2013). CLOCK/BMAL1 heterodimer 
forms the positive elements of the central oscillatory loop, which is thought to be the 
basis of circadian rhythms. (Gekakis et al., 1998) The main driver of circadian 
rhythms pivots around the E-box-mediated negative feedback loop, in which Period 
(PER) and Cryptochrome (CRY) proteins inhibit the complex CLOCK/BMAL1 
transcription activity. (Buhr and Takahashi, 2013) CLOCK/BMAL1 also controls the 
transcription of Rev-ERBα to periodically suppress BMAL1 expression, creating an 
additional feedback loop. (Preitner et al., 2002) In summary, fluctuations in the 
expression of multiple genes explain the 24-hour circadian rhythms of physiological 
processes. (Panda and Hogenesch, 2004) 
Circadian rhythms play an important role in human health. Studies have stated the 
role of it in affecting sleep, aging, cancer and vascular systems. (Jagannath et al., 
2013; Scheiermann et al., 2018; Kondratov et al., 2006; Kettner et al., 2014; Paschos 
and FitzGerald, 2010) However, the increase in the amount of unnatural light during 
the day and at night brought about by a modern industrialized lifestyle disrupts the 
homeostasis, which is suggested by external circadian rhythms. For cancer, several 
lines of evidence from previous studies suggested the relationships between cancer 
risk and circadian rhythm disruption. According to several studies, an increased risk 
of breast cancer was found among shift workers. (Davis et al., 2001; Schernhammer et 
al., 2001; Lie et al., 2006) The significant associations between breast cancer and 3 
single-nucleotide polymorphisms in CRY2 (rs11038689, rs7123390, and rs1401417) 
were identified. (Hoffman et al., 2010) Chu et al. found suggestive associations 
between prostate cancer risk and NPAS2 variants in men using finasteride, and SNP 
rs746924 remained statistically significant after Bonferroni correction (OR = 1.5, P = 
9.6 × 10-5). (Chu et al., 2018) In a case-control study in China, gene-based analysis 
highlighted a significant association between RORA and colorectal cancer risk. (Gu et 
al., 2018)  
Since genetic polymorphisms and changes in expression of circadian genes are 
considered strongly related with increased disease risk, genetic variations in circadian 
rhythms have been deeply researched in many epidemiological studies. Nonetheless, 
to date, only a few epidemiological studies have investigated the relationship between 
circadian genetic factors and cancer survival outcomes compared to cancer 
susceptibility. Therefore, there is a need to timely review the latest epidemiological 
studies on rhythm genes and cancer survival outcomes in order to expand knowledge 
about candidate cancer genes. 
 
Methods 
I have systematically searched the PubMed database using keywords “cancer” or 
“tumor” or “leukemia” or “carcinoma” or “lymphoma” or “melanoma” and 
“circadian” and “survival” for studies published until Mar 2021. The initial search 
identified 653 publications in the English language. Thirty papers of them met the 
criteria of having an epidemiological focus on cancer and examing the associations 
between genetic circadian factors and cancer survival. The following data was 
extracted from these studies: cancer type, circadian genetic factors, related health 
outcome, sample size, hazard ratio and p-value, tissue type, PMID and authors.  
I also searched Gene Expression database of Normal and Tumor tissues 2 
(GENT2) and Kaplan-Meier plotter for public circadian gene expression data to 
assess the effect of gene expression on survival in different cancer types. (Nagy et al., 
2021) By entering gene symbols of circadian genes and choosing tissue types, 
GENT2 and Kaplan Meier plotter will output Kaplan-Meier survival analysis and 
compare gene expression levels in tumor tissues. I assessed the expression level of 
PER1, PER2, PER3, CRY1, CRY2, BMAL1, CLOCK, NPAS2, NPAS3, TIMELESS, 
RORA, RORC, NR1D2, CK1ε, DEC1 and TIPIN on overall survival in all cancer 
types, and presented the significant results. The number of patients with available 
clinical data for each cancer type was shown in Table 1. Patients’ expression levels of 
circadian genes were split by median. GENT2 is freely available at 




Thirty epidemiological studies on circadian genetic factors and cancer survival 
have been conducted since 2009, and all of them reported significant relationships. 
The statistically significant associations between PERs, CRYs, BMAL1, CLOCK, 
NPASs, TIMELESS, RORA, RORC, NR1D2, CK1ε, DEC1 and TIPIN and cancer 
survival were indicated in 16 cancer types, including breast cancer, colorectal cancer, 
pancreatic cancer, gastric cancer, liver cancer, kidney cancer, endometrial cancer, lung 
cancer, prostate cancer, cervical cancer, diffuse large B-cell lymphoma, oral squamous 
cell carcinoma, head and neck squamous cell carcinoma, nasopharyngeal carcinoma, 
metastatic melanoma and soft tissue sarcoma (Table 2). All of the primary circadian 
genes were reported to play a role in cancer survival. The genetic factors investigated 
included both gene expression and variants. Most of them were gene expression, and 
10 were gene variants.  
Among 16 cancer types, survival outcomes of colorectal cancer, breast cancer, 
pancreatic cancer, kidney cancer, gastric cancer and liver cancer were found 
associated more than 5 genetic circadian factors (Figure 1A). Colorectal cancer was 
researched most, by 10 papers, and its survival was linked to 9 genetic circadian 
factors (Figure 1A and 1B). The significant findings between expression of CLOCK, 
CRY2 and NPAS2 and breast cancer survival, expression of CRY1 and PER3 and 
colorectal cancer survival, as well as expression of CRY2 and pancreatic cancer 
survival were indicated more than once and showed consistent results (Table 2). 
Cadenas et al. reported that higher expression of CRY2 was associated with better 
metastasis free survival of breast cancer, and Mao et al. found it was linked to longer 
overall survival. (Cadenas et al., 2014; Mao et al., 2015) For patients with colorectal 
cancer, higher expression of CRY1 was observed to have longer overall survival and 
higher five-year survival rate (Yu et al., 2013; Hasakova et al., 2018). Yu et al. 
reported that the 5-year survival rate of the high CRY1 expression group was 74.7%, 
which was significantly lower than that of the low expression group (89.1%). (Yu et 
al., 2013) According to Relles et al. and Qiu et al., higher percent survival at 2 years 
and longer overall survival of pancreatic cancer were related to higher expression of 
CRY2. The percent survival at 2 years of patients with low CRY2 expression was 
22.3%, while that of patients with high expression was 43.9%. (Relles et al., 2012) 
Expression and variants of these genes were observed to have positive or negative 
effect on cancer survival (Figure 2). Higher expression of PER1, PER2, PER3, CRY2, 
BMAL1, CLOCK, NPAS2, TIMELESS, RORA, RORC, NR1D2, CK1ε and TIPIN 
showed protective effects on cancer survival. By contrast, homogeneous expression of 
PER2 or BMAL1, and higher expression of CRY1, TIMELESS and DEC1 indicated 
negative effects on cancer survival. Interestingly, expression of PER1, PER2, PER3, 
CRY2, BMAL1, CLOCK, NPAS2, TIMELESS and RORA were associated with more 
than one cancer type. Besides, for the same gene, consistent directions of its effect 
were found across different cancer types. Higher expression of PER1 was related to 
better cancer survival in 6 cancer types, including breast cancer, colorectal cancer, 
pancreatic cancer, kidney cancer, endometrial cancer, and non-small cell lung cancer. 
Expression of PER2, PER3, and CRY2 was associated with survival of 5 different 
types of cancer. Expression of BMAL1, CLOCK and NPAS2 was related to 4 types of 
cancer, as well as expression of RORA was linked to 2 types of cancer. However, 
significantly shorter survival was associated with higher expression of TIMELESS in 
patients having breast cancer, liver cancer, kidney cancer, lung cancer, cervical cancer. 
Thirteen single nucleotide polymorphisms (SNPs) were recognized in PER1, 
PER2, PER3, CRY1, CLOCK, NPAS2, NPAS3 and RORA, indicating several 
statistically significant associations between circadian SNPs and cancer survival. SNP 
rs3027178 in PER1, SNP rs7602358 in PER2, SNP rs228729 in PER3, SNP 
rs11133399 in CLOCK, SNP rs2279284 in BAML1, SNP rs1053096 in NPAS2 and 
SNP rs2305160 in NPAS3 posed negative effects on patients’ survival with cancer. 
SNP rs3027178 in PER1, SNP rs228729 in PER3, SNP rs11133399 and SNP 
rs2279284 in BAML1 in CLOCK were significantly related to an increased death risk 
in gastric cancer patients. (Qu et al., 2016; Chen et al., 2019) Epidemiological study 
of Yuan et al. indicated that SNP rs1053096 in NPAS2 and SNP rs2305160 in NPAS3 
increased overall death risk of hepatocellular carcinoma patients in the recessive 
model and the dominant model. (Yuan et al., 2014) In soft tissue sarcoma, SNP 
rs7602358 in PER2 had detrimental effects on patients’ survival. (Benna et al., 2018)  
On opposite, SNP rs2640908 in PER3, SNP rs1056560 in CRY1, SNP rs3749474 
and SNP rs1801260 in CLOCK, SNP rs1044432 in BAML1 and SNP rs76436997 in 
RORA had significant protective effect on cancer survival. In hepatocellular 
carcinoma, patients who carried at least one variant allele of SNP rs2640908 in PER3 
had a significantly decreased risk of death compared with those carrying homozygous 
wild-type alleles (11.6 months vs. 8.1 months). (Zhao et al., 2012) SNP rs1056560 in 
CRY1 and SNP rs1044432 in BAML1 exhibited a significant protective effect on the 
overall survival in patients with gastric cancer. (Qu et al., 2016; Chen et al., 2019) For 
colorectal cancer patients, SNP rs3749474 and SNP rs1801260 in CLOCK and SNP 
rs76436997 in RORA increased their overall survival time. (Gu et al., 2018; Zhou et 
al., 2012)  
The significant results of Kaplan Meier survival analysis using GENT2 database 
are shown in Fig. 3. The overall survival of patients in 7 cancer types (breast cancer, 
blood cancer, brain cancer, lung cancer, ovarian cancer, colon cancer and stomach 
cancer) were associated with circadian gene expression levels. In this analysis, 
expression of PER2, PER3, CRY2, NR1D2, CLOCK and NPAS3 did not show 
detrimental effects on cancer survival. Interestingly, expression of PER2, PER3, 
CRY2, NR1D2, CLOCK also only indicated protective effects on cancer survival 
among the types of cancer that have been studied in my review. Among these six 
genes, high PER2 expression levels were related to significantly better overall 
survival in 4 types of cancer, including breast cancer, blood cancer, brain cancer and 
ovarian cancer. High expression of PER3 were linked to significantly better overall 
survival in patients with breast cancer, blood cancer and brain cancer. PER1, CRY1, 
BMAL1, NPAS2, RORA, RORC, DEC1 and TIPIN showed different effects (protective 
or detrimental) on overall survival in different cancer types. What’s more, patients 
with breast cancer in the high PER1, PER2, PER3, CRY2 and RORC expression group 
had significant longer overall survival than those in the low expression group. The 
result was consistent with Cadenas et al.’s study which also indicating the protective 
effects of PER1, PER2, PER3, CRY2 and RORC in breast cancer survival. 
I also performed the Kaplan Meier survival analysis to assess the effects of 
circadian genes on survival in 21 cancer types using Kaplan-Meier plotter database. 
The complete results were provided in the Supplemental Figures. Figure 4 showed the 
results of PER2, PER3, RORA, RORC, DEC1 and TIMELESS. PER2, PER3, RORA 
and RORC did not showed significantly negative effects on survival in these 21 types 
of cancer. PER2 was found associated with survival of kidney renal clear cell 
carcinoma and pancreatic ductal adenocarcinoma. PER3 was related to survival of 
kidney renal clear cell carcinoma and cervical squamous cell carcinoma. RORA had 
significantly protective effects on kidney renal clear cell carcinoma, kidney renal 
papillary cell carcinoma and lung adenocarcinoma. Compared with low expression 
group, high expression levels of RORC indicated longer overall survival in patients 
with kidney renal clear cell carcinoma, esophageal adenocarcinoma, bladder 
Carcinoma, liver hepatocellular carcinoma, thymoma and thyroid carcinoma. On the 
contrary, DEC1 only showed significantly detrimental effects in this analysis, and 
high expression of DEC1 was correlated with worse overall survival in kidney renal 
clear cell carcinoma and lung adenocarcinoma. Besides, TIMELESS was observed to 
play a protective or detrimental role based on different cancer types. High expression 
of TIMELESS suggested significantly longer overall survival in patients with kidney 
renal clear cell carcinoma, liver hepatocellular carcinoma, lung adenocarcinoma or 
sarcoma. For cervical squamous cell carcinoma, stomach adenocarcinoma thyroid 
carcinoma, thymoma and esophageal squamous cell carcinoma, patients with high 




In this study, I reviewed and investigated the associations between circadian 
genetic factors and cancer survival across different cancer types. According to my 
review of 30 papers, PER1, PER2, PER3, CRY1, CRY2, BMAL1, CLOCK, NPAS2, 
NPAS3, TIMELESS, RORA, RORC, NR1D2, CK1ε, DEC1 and TIPIN were 
significantly related to patients’ survival in 16 types of cancer, including breast 
cancer, colorectal cancer, pancreatic cancer, gastric cancer, liver cancer, kidney 
cancer, endometrial cancer, lung cancer, prostate cancer, cervical cancer, diffuse large 
B-cell lymphoma, oral squamous cell carcinoma, head and neck squamous cell 
carcinoma, nasopharyngeal carcinoma, metastatic melanoma and soft tissue sarcoma. 
The results of the review are consistent, indicating that circadian genes may play a 
role in cancer survival. Furthermore, I conducted survival analysis using GENT2 and 
Kaplan-Meier plotter database, which also indicated what expression level of 
circadian genes was significantly associated with cancer overall survival.  
Our results suggested that the associations between circadian genes and cancer 
survival differed among different genes and cancer types. Circadian genes may act 
dissimilar roles in different tumor environments and organisms, showing the 
complexity of the circadian transcriptional loops. For example, TIMELESS was 
associated with poorer survival in patients with ovarian cancer but better survival in 
cervical squamous cell carcinoma, while others, such as PER2 and PER3, were 
associated with better survival in patients with kidney renal clear cell carcinoma. 
TIMELESS is known to be a positive regulator of DNA replication and TIMELESS-
TIPIN functions as a replication fork stabilizer. (Leman et al., 2010) TIMELESS 
depletion increases γH2AX and causes G2 / M arrest, restricting cell proliferation. 
Activation of ERK can lead to the over-expression of TIMELESS in cancer, which 
stimulates the proliferation of cancer cells. (Neilsen et al., 2019) Differently, P53 is an 
important anti-cancer gene, and previous studies have shown that reducing the 
expression of PER2 can directly depress the activation of P53 protein, thus 
accelerating the development of tumor. (Fu et al., 2002) However, the exact molecular 
mechanisms behind the complex clock mechanism are still largely unknown. Further 
confirmation of the complex function of the biological circadian rhythm in cancer is 
needed in the future. 
The circadian genetic factors identified included both gene expression and SNPs. 
SNPs can cause disruption to circadian rhythms and alterations in gene expression, 
but a single SNP may provide moderate or undetectable effects. Besides, the analysis 
of SNPs needs reference alleles. When genotype or frequency data are available, it 
may only be known which allele is dominant and which allele is minor in a particular 
population. As a result, interpretation of polymorphism varies, depending on the type 
of cancer or the population in which it is being evaluated. Relatively, gene expression 
is related to the function of genes, and its biological significance is easier to be 
interpreted. However, the examination of SNPs is relatively convenient. Venous blood 
is the most commonly sampled specimen and can be easily obtained by venipuncture, 
while the examination of gene expression usually needs tissue samples. It is suggested 
to test the association between SNP and disease more effectively by jointly modeling 
the relationship between SNP, gene expression and disease. (Huang et al., 2014) 
Overall, these results need to be interpreted with caution and further validated in more 
studies. 
However, there existed some inconsistent results between the review and the 
public databases. Zhang et al. revealed that an increase in the expression of 
TIMELESS was linked to poorer overall survival and disease-free survival in early-
stage cervical carcinoma. (Zhang et al., 2016) Our results based on Kaplan-Meier 
plotter database suggested that higher expression of TIMELESS was related to 
significantly better overall survival in patients with cervical squamous cell carcinoma. 
The discrepancy of the results may be partly explained by different tumor subtypes or 
stages. Several CLOCK genes were differentially expressed between tumor stages and 
showed significant differences in different patient subtypes within cancer types, 
suggesting that CLOCK genes may be altered during tumor progression. (Ye et al., 
2018) Different tumor subtypes or stages may have different genomic patterns and 
influence the relationship between circadian genes and prognosis. The studies used 
different study population. In Zhang et al.’s study, tumor specimens were collected 
from 189 patients with cervical cancer who underwent surgical treatment in the 
Cancer Center of Sun Yat-sen University from 2006 to 2010. (Zhang et al., 2016) 
GENT2 used gene expression profiles from more than 34,000 samples of different 
human cancer and normal tissues generated by the Affymetrix U133A or U133Plus2 
microarray platform. (Park et al., 2019) Besides, the study population may have 
different treatment of cancer after surgery, which can also become a confounder. 
What’s more, in the review, all the associations between circadian factors and cancer 
survival were significant. However, in the study using GENT2 and Kaplan-Meier 
plotter, quite a number of the results between circadian factors and cancer survival 
were not significant. It may be due to the publish bias that authors publish only results 
that show a significant finding disturbs the balance of findings. 
This study had several limitations. Most of the significant associations were not 
replicated more than once. Besides, the study did not stratify tumors according to 
stages and molecular subtypes. There are still huge gaps in the understanding of the 
association between circadian genes and different types of cancer, different subtypes 
of cancer, and different stages of cancer. What’s more, the timing of the acquisition of 
biological samples from cancer patients is unknown, which may result in significant 
differences in the omics data. (Ye et al., 2018) Because the results lack complete 
consistency, these potential biomarkers should not be used to make clinical decisions 
related to cancer treatment at this time. However, these findings warrant the need for 
further research and make the area a focus of research. Future research fields of the 
clinical implications of circadian genetic factors may include indicating survival, 
serving as potential treatment targets and supporting cancer chrono therapy. 
With the development of genomic technology, molecular diagnosis has been 
widely used in cancer diagnosis, and more and more biomarkers have been developed. 
Mutations in genes such as BRCA1 and BRCA2 may increase the risk of breast, 
ovarian and other cancers, which have been used as biomarkers for cancer risk in 
clinical practice. (Chen and Parmigiani, 2007) The findings from this study suggest 
that dysfunctions or functional clocks may become the candidate of indicators of 
cancer survival and therapeutic response outcomes. Biomarker testing can help 
personalize the management of cancer and help cancer patients make better treatment 
decisions, thereby reducing cancer mortality. The clinical applicability of biomarkers 
is one of the most challenging parts of converting research results into practical 
applications. In order to apply these results to maximize patient benefits, the 
effectiveness of markers should be evaluated using the disciplined application of well-
designed clinical trials. 
Uncovering the function of genes linked to cancer and finding less harmful ways 
to improve cancer outcomes has long been the focus of cancer researchers around the 
world. Currently, targeted therapy is the focal point of anticancer drug development. 
Effective identification of potential targets that play essential roles in the growth and 
survival of cancer cell is required by the realization of targeted therapies. In this study, 
the significant associations between circadian genetic factors and cancer survival may 
help find potential therapeutic targets for cancer. If activators of positive regulator 
circadian genes or inhibitors of negative regulator circadian genes can be developed, 
it may be possible to use them as treatments and effectively improve patients’ 
survival.  
Understanding the role and relationship of clock genes in cancer provides an 
important basis for the development of timed therapy for cancer. The influence of 
circadian rhythm biology on the system level has been recognized in the field of 
chronotherapy. In essence, the field seeks to understand how time of day affects the 
efficacy, metabolism, toxicity, and off-target effects of therapeutic agents. (Levi and 
Schibler, 2007) The concept of circadian-rhythm-based cancer treatment has also 
developed rapidly, whose basic objective is to improve the effectiveness of 
chemotherapy drugs as well as minimize adverse reactions through appropriate timing 
of administration. Giacchetti et al. conducted a meta-analysis on the effects of 
circadian chemotherapy on patients’ survival with metastatic colorectal cancer, 
finding that overall survival was significantly improved in males on chrono 
modulated chemotherapy (median values of 20.8 months) rather than on conventional 
chemotherapy (median values of 17.5 months). (Giacchetti et al., 2012) Giving drugs 
at a time with relative high expression level of positive regulator genes and low 
expression level of negative regulator genes may facilitate the development of 
effective new anticancer drugs or improved drug delivery plans and ultimately 
improve patients’ health. By modeling, simulation of complex systems and clinical 
trials, it may help determine the optimal model structure and parameters, as well as 
the proper time. Currently, circadian rhythm studies are not yet a routine part of drug 
safety and efficacy trials, and the effects of the duration on most drugs on the market 
has not been widely explored. In the future, timed therapy focusing on circadian gene 




This study reviewed and demonstrated the significant associations between 
circadian genetic factors and cancer survival across different cancer types. Although 
results have been achieved in this area of research, clinical trials important to exploit 
them have not yet been carried out. More research is warranted before circadian 











Table 1. Sample size for each cancer type in GENT2 and KM Plotter. 
 
Database Cancer Type Sample Size 
GENT2 breast cancer 502 
 blood cancer 554 
 brain cancer 50 
 colon cancer 1003 
 lung cancer 445 
 ovary cancer 166 
 stomach cancer 300 
KM Plotter Bladder Carcinoma  405 
 Breast cancer  1090 
 Cervical squamous cell carcinoma  304 
 Esophageal Adenocarcinoma  80 
 Esophageal Squamous Cell Carcinoma   81 
 Head-neck squamous cell carcinoma  500 
 Kidney renal clear cell carcinoma  530 
 Kidney renal papillary cell carcinoma  288 
 Liver hepatocellular carcinoma  371 
 Lung adenocarcinoma  513 
 Lung squamous cell carcinoma  501 
 Ovarian cancer  374 
 Pancreatic ductal adenocarcinoma  177 
 Pheochromocytoma and Paraganglioma  178 
 Rectum adenocarcinoma  165 
 Sarcoma  259 
 Stomach adenocarcinoma  375 
 Testicular Germ Cell Tumor  134 
 Thymoma  119 
 Thyroid carcinoma  502 







Table 2. Summary of significant associations between circadian genetic factors 
and cancer survival. 
 
Figure 1. A. The number of circadian factors related with cancer survival by 
cancer type. B. The number of papers indicating associations between circadian 
















































Figure 3. The Kaplan Meier survival curves for cancer patients with high and low circadian 
gene expression using GENT2 database. It includes fifteen genes: PER1, PER2, PER3, CRY1, 
























Figure 4. The Kaplan Meier survival curves for cancer patients with high and low circadian 
gene expression using Kaplan-Meier plotter database. It includes six genes: PER2, PER3, 








Figure 5. The Kaplan Meier survival curves for cancer patients with high and low circadian 
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